



**Contra Costa Health Plan**  
**P&T Formulary Update**  
**March 2, 2023**

**Changes effective: 03/27/2023**

**Contra Costa Health Plan Pharmacy & Therapeutics (P&T) Committee Decisions**

*On March 2, 2023 the CCHP P&T Committee reviewed the following Therapeutic Classes, Drug Monographs and PA criteria for efficacy, safety, utilization, cost and safety:*

Therapeutic Class Reviews	
<ul style="list-style-type: none"><li>• Sickle Cell Agents</li><li>• Anti-obesity medications</li><li>• Calcium channel blockers</li><li>• Pulmonary arterial hypertension</li><li>• Second generation antihistamines</li></ul>	<ul style="list-style-type: none"><li>• Inhaled anticholinergics</li><li>• Direct oral anticoagulants</li><li>• Specialty Biologic Agents</li></ul>
Drug Monographs	
<ul style="list-style-type: none"><li>• Hemgenix</li></ul>	
Prior Authorization Criteria Updates	
<p><u>New criteria was created for the following agents:</u></p> <ul style="list-style-type: none"><li>• Akynzeo</li><li>• Oxbryta</li><li>• Siklos</li></ul> <p><u>Updates were made to the criteria for the following agents:</u></p> <ul style="list-style-type: none"><li>• Anti-obesity medications</li><li>• Evolocumab (Repatha), Praluent (alirocumab)</li><li>• Pulmonary Arterial Hypertension agents</li></ul> <p><u>Criteria reviewed and unchanged:</u></p> <ul style="list-style-type: none"><li>• Second generation antihistamines</li><li>• Inhaled anticholinergics</li><li>• Direct oral anticoagulants</li><li>• Methergine</li><li>• Specialty Biologic Agents</li></ul> <p><u>CCHP formulary changes were made to the following drugs:</u></p> <ul style="list-style-type: none"><li>• Calcium channel blockers</li><li>• Pulmonary Arterial Hypertension</li></ul>	

Guest Speaker(s)	
<ul style="list-style-type: none"> <li>None</li> </ul>	
<b><u>CCHP P&amp;T Committee approved the following modifications to the formulary (commercial and BHC members):</u></b>	
Medication Name & Dosage Strength	Approved Formulary Changes
Amlodipine-atorvastatin (Caduet)	Remove from Tier 1 formulary
Nicardipine intravenous	Remove from Tier 1 formulary
Verapamil intravenous soln	Remove from Tier 1 formulary
Diltiazem intravenous soln	Remove from Tier 1 formulary
Neostigmine IV syringe	Add to formulary as Tier 3 PA
Xalkori capsule	Add to formulary as Tier 3 PA
Lacosamide tablet	Add to Formulary as Tier 1
Bosentan tablet	Add to formulary as Tier 3 PA
Tracleer suspension	Add to formulary as Tier 3 PA
Opsumit	Add to formulary as Tier 3 PA
Ambrisentan	Add to formulary as Tier 3 PA
Treprostinil injection soln	Add to formulary as Tier 3 PA
Tyvaso	Add to formulary as Tier 3 PA
Orenitram	Add to formulary as Tier 3 PA
Adempas	Add to formulary as Tier 3 PA
Uptravi	Add to formulary as Tier 3 PA
Siklos tablet	Add to formulary as Tier 3 PA
Oxbryta tablet	Add to formulary as Tier 3 PA
Akynzeo	Add to formulary as Tier 3 PA
New Product Reviews (including new indications)	
<ul style="list-style-type: none"> <li>Floseal (thrombin/gelatin) topical kit</li> <li>Tauvid (flortaucipir f-18) IV solution</li> <li>Tembexa (brincidofovir) 10mg/ml oral suspension</li> <li>Tpoxx (tecovirim at) IV solution</li> <li>Tascenso ODT (fingolimod) tablet</li> <li>Caplyta (lumateperone) capsule</li> <li>Zoryve (roflumilast) 0.5% cream</li> <li>Calquence (acalabrutinib) tablet</li> <li>Esbriet (pirfenidone) tablet</li> <li>Xaciato (clindamycin) 2% vaginal gel</li> <li>Zynteglo (Zynteglo) IV suspension</li> <li>Ryaltris (olopatatine-mometasone) nasal spray</li> <li>Cytalux (pafolacianine) IV vial</li> </ul>	